专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明专利

AU2008254061B2 1-substituted tetrahydroisoquinoline compound 未知
公开(公告)号：AU2008254061B2
公开(公告)日：2012-06-14
申请号：AU2008254061
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： OGIYAMA TAKASHI , SHISHIKURA JUN-ICHI , YONEZAWA KOICHI , OKADA HIDETSUGU , INOUE MAKOTO , YOKOYAMA KAZUHIRO , KAKIMOTO SHUICHIROU , YAMAKI SUSUMU
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/056
摘要： Provided is a compound useful as an N-type Ca 2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca 2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca 2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

3. 发明专利

BRPI0811145A2 未知
公开(公告)号：BRPI0811145A2
公开(公告)日：2014-12-23
申请号：BRPI0811145
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： SHISHIKURA JUN-ICHI , INOUE MAKOTO , OGIYAMA TAKASHI , YONEZAWA KOICHI , YAMAKI SUSUMU , YOKOYAMA KAZUHIRO , KAMIMOTO SHUICHIROU , OKADA HIDETSUGU
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/056
摘要： Provided is a compound useful as an N-type Ca 2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca 2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca 2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

4. 发明公开

EP2149560A4 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND 有权
标题翻译： 1-取代四氢异喹啉CONNECTION
公开(公告)号：EP2149560A4
公开(公告)日：2011-01-05
申请号：EP08764424
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： SHISHIKURA JUN-ICHI , INOUE MAKOTO , OGIYAMA TAKASHI , YONEZAWA KOICHI , YAMAKI SUSUMU , YOKOYAMA KAZUHIRO , KAKIMOTO SHUICHIROU , OKADA HIDETSUGU
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12
CPC分类号： C07D217/04 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/06

5. 发明专利

ES2537803T3 Compuesto de tetrahidroisoquinolina 1-sustituida 未知
公开(公告)号：ES2537803T3
公开(公告)日：2015-06-12
申请号：ES08764424
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： SHISHIKURA JUN-ICHI , INOUE MAKOTO , OGIYAMA TAKASHI , YONEZAWA KOICHI , YAMAKI SUSUMU , YOKOYAMA KAZUHIRO , KAKIMOTO SHUICHIROU , OKADA HIDETSUGU
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12
摘要： Un compuesto seleccionado del grupo constituido por: 1-[({2-[(1S)-1-ciclohexil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, (2S)-1-({2-[(1S)-1-ciclohexil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)-3-metoxi propan-2-ol, 1-({[2-(1 (1S)-isopropil-6-metoxi-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, (2R)-1-({2-[(1S)-8-metoxi-1-fenil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)propan-2-ol, 1-[({2-[(1R)-7-etil-1-(metoximetil)-3,4-dihidroisoquinolin-2 (1H)-il]-2-oxoetil}amino)metil]ciclohexanol, (2S)-1-metoxi-3-[(2-oxo-2-{1 (1S)-[2-(trifluorometil)bencil]-3,4-dihidroisoquinolin-2(1H)-il}etil)amino]propan-2-ol, 1-({[3-(1-ciclohexil-3,4-dihidroisoquinolin-2(1H)-il)-3-oxo propil]amino}metil)ciclohexanol, (2R)-1-{[2-(1-ciclohexil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}propan-2-ol, (2R)-1-[(2-oxo-2-{1-[2-(trifluorometil)fenil]-3,4-dihidroisoquinolin-2(1H)-il}etil)amino]propan-2-ol, (2S)-1-{[2-(1-ciclohexil-7-metil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}-3-metoxi propan-2-ol, (2R)-1-({2-oxo-2-[(1S)-1-fenil-3,4-dihidroisoquinolin-2(1H)-il]etil}amino)propan-2-ol, 1-[({2-[7-fluoro-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-[({2-[7-etil-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-({[2-(1-isopropil-6-metoxi-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1-[({2-[5-metoxi-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-[({2-[1-(metoximetil)-6-metil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, (1S,2S)-2-{[2-(1-ciclohexil-3,4-dihidroisaquinolin-2(1H)-il)-2-oxoetil]amino}-1-fenil propano-1,3-diol, 1-({(2R)-2-[(1-ciclohexil-3,4-dihidroisoquinolin-2(1H)-il)carbonil]pirrolidin-1-il}metil)ciclohexanol, (2R)-1-{[2-(1-ciclohexil-1-metil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}-propan-2-ol, 1-({[2-(3',4'-dihidro-2'H-espiro [ciclohexano-1,1'-isoquinolin]-2'-il)-2-oxoetil]amino}metil)ciclohexanol, (2R)-1-[(2-oxo-2-{1-[2-(trifluorometoxi)fenil]-3,4-dihidroisoquinolin-2(1H)-il}etil)amino]propan-2-ol, (2R)-1-{[2-(1-ciclohexil-7-etil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}-propan-2-ol, 1-({[2-(6-fluoro-1-isopropil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1,1-diciclopropil-2-({2-[6-fluoro-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)etanol, 1-({[2-(1-terc-butil-8-metoxi-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1-({[2-(1-isopropil-6-metil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1-({[2-(6-fluoro-1-propil-3,4-dihidroisoquinolin-2(1H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1-[({2-[1-(metoximetil)-7-metil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-({[2-(5-fluoro-1-propil-3,4-dihidroisoquinolin-2(H)-il)-2-oxoetil]amino}metil)ciclohexanol, 1-[({2-[5-fluoro-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-[({2-[8-metoxi-1-(metoximetil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, 1-[({2-[1-(etoximetil)-7-metil-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)metil]ciclohexanol, y (1R,2S)-2-({2-[(1R)-1-(2-metoxifenil)-3,4-dihidroisoquinolin-2(1H)-il]-2-oxoetil}amino)ciclopentanol; o una sal farmacéuticamente aceptable de los mismos.

6. 发明专利

MX2009012610A COMPUESTO DE TETRAHIDROISOQUINOLINA 1-SUSTITUIDO. 未知
公开(公告)号：MX2009012610A
公开(公告)日：2009-12-11
申请号：MX2009012610
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： YOKOYAMA KAZUHIRO , INOUE MAKOTO , YONEZAWA KOICHI , SHISHIKUR -ICHI JUN , OGIYAMA TAKASHI , YAMAKI SUSUMU , KAKIMOTO SHUICHIROU , OKADA HIDETSUGU
IPC分类号： A61K31/4355 , C07D217/04 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/056
摘要： Se pretende proporcionar un compuesto útil como un bloqueador del canal de Ca2+ de tipo N. Como resultado de estudios intensivos de compuestos que tienen una acción de bloqueo del canal de Ca2+ de tipo N, los presentes inventores encontraron que un compuesto de tetrahidroisoquinolina de la invención que tiene un sustituyente en la posición 1 tiene una acción de bloqueo del canal de Ca2+ de tipo N, una acción antinociceptiva sobre el dolor, una acción antineuropática sobre el dolor, una acción inhibidora del dolor abdominal y una acción mejoradora sobre el estreñimiento inducido por opioide, y por ello se ha llevado a cabo la invención. El compuesto de la invención se puede usar como una composición farmacéutica profiláctica y/o terapéutica para diversos dolores, tales como el dolor neuropático y el dolor nociceptivo, dolores de cabeza tales como migraña y dolor de cabeza en racimo, enfermedades del sistema nervioso central tales como ansiedad, depresión, epilepsia, derrame cerebral y síndrome de pierna inquieta, síntomas abdominales, tales como dolor abdominal y distensión abdominal, anormalidades en las heces tales como diarrea y estreñimiento, enfermedades del sistema digestivo tales como síndrome de intestino irritable, enfermedades urológicas, tales como vejiga hiperactiva y cistitis intersticial, y otros.

8. 发明专利

CA2687958A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND 未知
公开(公告)号：CA2687958A1
公开(公告)日：2008-11-27
申请号：CA2687958
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： OKADA HIDETSUGU , INOUE MAKOTO , OGIYAMA TAKASHI , YONEZAWA KOICHI , YAMAKI SUSUMU , KAKIMOTO SHUICHIROU , SHISHIKURA JUN-ICHI , YOKOYAMA KAZUHIRO
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/056
摘要： It is intended to provide a compound useful as an N-type Ca2+ channel blo cker. As a result of intensive studies of compounds having an action of bloc king the N-type Ca2+ channel, the present inventors found that a tetrahydroi soquinoline compound of the invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channel, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain inhibitory action and an opioid-induced constipation-improving action, and thus the invention has been completed. The compound of the invention can be used as a prophylac tic and/or therapeutic pharmaceutical composition for various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluste r headache, central nervous system diseases such as anxiety, depression, epi lepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such a s abdominal pain and abdominal distension, stool abnormalities such as diarr hea and constipation, digestive system diseases such as irritable bowel synd rome, urologic diseases such as overactive bladder and interstitial cystitis , etc.

9. 发明专利

AU2008254061A1 1-substituted tetrahydroisoquinoline compound 未知
公开(公告)号：AU2008254061A1
公开(公告)日：2008-11-27
申请号：AU2008254061
申请日：2008-05-20
申请人： ASTELLAS PHARMA INC
发明人： OGIYAMA TAKASHI , SHISHIKURA JUN-ICHI , YONEZAWA KOICHI , OKADA HIDETSUGU , INOUE MAKOTO , YOKOYAMA KAZUHIRO , KAKIMOTO SHUICHIROU , YAMAKI SUSUMU
IPC分类号： C07D217/04 , A61K31/4355 , A61K31/472 , A61K31/4725 , A61K31/4747 , A61K31/496 , A61P1/00 , A61P9/00 , A61P13/10 , A61P25/04 , A61P25/06 , A61P25/10 , A61P25/22 , A61P25/24 , A61P43/00 , C07D217/14 , C07D217/16 , C07D221/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D491/056
摘要： Provided is a compound useful as an N-type Ca 2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca 2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca 2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式